Compare SPDR Kensho Final Frontiers ETF (ROKT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Kensho Final Frontiers ETF vs Zimmer Biomet Holdings Inc — how do they compare? SPDR Kensho Final Frontiers ETF trades at $102.69 (market cap $170.14M), while Zimmer Biomet Holdings Inc trades at $88.71 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 99.6× SPDR Kensho Final Frontiers ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Kensho Final Frontiers ETF for 9 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ROKT | ZBH | |
|---|---|---|
Market Cap | $170.14M | $16.95B |
Volume | 12,298 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $136.68 | $103.98 |
52-Week Low | $72.93 | $79.58 |
Typical Hold Time | 9 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
